Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma

the common standard-of-care comparator arms and showed no statistically significant differences. Safety analyses were unanchored, showing liso-cel had lower odds (95% confidence interval) of grade ≥3 serious treatment-emergent adverse events 0.49 (0.27-0.90), cytokine release syndrome any grade, 0.09 (0.04-0.18); grade ≥3, 0.09 (0.01-0.75), and neurological events any grade, 0.08 (0.03-0.18); grade ≥3, 0.21 (0.06-0.68). In this MAIC, liso-cel demonstrated comparable efficacy and a more favorable safety profile versus axi-cel for 2L treatment of R/R LBCL.